Persistence of HBV Vaccine's Protection and Response to Hepatitis B Booster Immunization in 5-to 7-Year-Old Children in the Kohgiloyeh and Boyerahmad Province, Iran

被引:0
作者
Yazdanpanah, Behrouz [2 ]
Safari, Mitra [1 ]
Yazdanpanah, Shahrzad [3 ]
机构
[1] Yasouj Univ Med Sci, Sch Nursing & Midwifery, Yasuj, Iran
[2] Yasouj Univ Med Sci, Sch Paramed, Yasuj, Iran
[3] Yasouj Univ Med Sci, Sch Med, Yasuj, Iran
关键词
Hepatitis B Vaccine; Booster dose; Immune Protection; LONG-TERM PERSISTENCE; ANTI-HBS; IMMUNOLOGICAL MEMORY; VACCINATION; IMMUNITY; BIRTH; ADOLESCENTS; ANTIBODIES; DURATION; INFANCY;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims: The duration of the protection of hepatitis B vaccination for infants and the necessity of a booster dose administration is unknown. The aim of the present study was to evaluate the persistence of seroprotection after hepatitis B virus (HBV) vaccination in order to determine the necessity of a single booster dose in 5- to 7-year-old children. Methods: This clinical trial study was conducted from 2004 to 2005. The study population included all children aged 5 to 7 years old in the Kohgiloyeh and Boyerahmad province who had been vaccinated starting at birth with hepatitis B vaccine. Among these children, 729 were selected via a multiple-stage sampling method. Parents gave their informed consent, and blood specimens (3 ml) were obtained from children. Hepatitis B surface antibody (HBsAb) and hepatitis B surface antigen (HBsAg) were determined by enzyme-linked immunosorbent assay (ELISA). Subjects with nonprotective titer levels (< 10 mIU/ml) received a booster does of the DNA recombinant vaccine. Four weeks after the administration of a booster dose, the antibody to HBsAg (anti-HBs) titer was measured. Data were analyzed using SPSS software, and analyses included chi-square, ANOVA, and independent-samples and paired-samples t-tests. Results: 615 children (84.4%) had a protective antibody titer. The mean antibody titer was 230.5 +/- 308.9 IU/ml, with a range of 10.6 to 1175 IU/ml. 15.6% of subjects had a nonprotective antibody titer, and the mean antibody titer was 4.97 +/- 3.5 IU/ml. All subjects were HBsAg negative. No statistically significant differences were found by sex or by urban versus rural area of residence. The seroprotection rates significantly decreased by as the age of the children increased. Following the booster dose, 78.1 % of the children had a protective titer, and the mean titer significantly increased from 4.97 +/- 3.5 at birth to 332.1 +/- 402 IU/ml after the booster (P < 0.001). Conclusions: According to our results, the proper response of the immune system to a booster dose of HBV at 5 to 7 years of age reveals that immunologic memory is good after primary vaccination. Administration of booster dose does not appear to be necessary at these ages even though these children have a greater possibility of exposure to HBV in school age.
引用
收藏
页码:17 / 21
页数:5
相关论文
共 35 条
[1]  
[Anonymous], 2005, PRINCIPLES PRACTICE
[2]  
BEHJATI M, 2002, J SHAHEED SADOUGHI U, V10, P3
[3]   Early immunisation with hepatitis B vaccine: a five-year study [J].
Belloni, C ;
Pistorio, A ;
Tinelli, C ;
Komakec, J ;
Chirico, G ;
Rovelli, D ;
Gulminetti, R ;
Comolli, G ;
Orsolini, P ;
Rondini, G .
VACCINE, 2000, 18 (14) :1307-1311
[4]   Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low [J].
Boxall, EH ;
Sira, JA ;
El-Shuhkri, N ;
Kelly, DA .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (07) :1264-1269
[5]   IMMUNOGENICITY OF A RECOMBINANT PRE-S2-CONTAINING HEPATITIS-B VACCINE VERSUS PLASMA-DERIVED VACCINE ADMINISTERED AS A BOOSTER [J].
BUCHER, B ;
FRANCIOLI, P ;
GEUDELIN, B ;
FRITZELL, B ;
LAVANCHY, D ;
FREI, PC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1994, 13 (03) :212-217
[6]  
DENTINGER C, 2002, INF DIS SOC AM ANN M, P177
[7]   Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth [J].
Dentinger, CM ;
McMahon, BJ ;
Butler, JC ;
Dunaway, CE ;
Zanis, CL ;
Bulkow, LR ;
Bruden, DL ;
Nainan, OV ;
Khristova, ML ;
Hennessy, TW ;
Parkinson, AJ .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (09) :786-792
[8]   Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers [J].
Floreani, A ;
Baldo, V ;
Cristofoletti, M ;
Renzulli, G ;
Valeri, A ;
Zanetti, C ;
Trivello, R .
VACCINE, 2004, 22 (5-6) :607-610
[9]   QUANTIFICATION OF HEPATITIS-B VACCINE-INDUCED ANTIBODIES AS A PREDICTOR OF ANTI-HBS PERSISTENCE [J].
GESEMANN, M ;
SCHEIERMANN, N .
VACCINE, 1995, 13 (05) :443-447
[10]   Decreased immune response to hepatitis B eight years after routine vaccination in Israel [J].
Gold, Y ;
Somech, R ;
Mandel, D ;
Peled, Y ;
Reif, S .
ACTA PAEDIATRICA, 2003, 92 (10) :1158-1162